Pages that link to "Q64387019"

The following pages link to Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts (Q64387019):

Displaying 39 items.

• Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target (Q24608574) (← links)
• Current State of Animal (Mouse) Modeling in Melanoma Research (Q26781652) (← links)
• Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment (Q26829125) (← links)
• One mouse, one patient paradigm: New avatars of personalized cancer therapy (Q27023342) (← links)
• Current status and evolution of preclinical drug development models of epithelial ovarian cancer (Q27028117) (← links)
• Preclinical mouse cancer models: a maze of opportunities and challenges (Q27322080) (← links)
• Prioritizing therapeutic targets using patient-derived xenograft models (Q28083993) (← links)
• Single cell resolution in vivo imaging of DNA damage following PARP inhibition (Q30650918) (← links)
• Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses (Q33415400) (← links)
• Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy (Q33418574) (← links)
• The role of BRCA status on the prognosis of patients with epithelial ovarian cancer: a systematic review of the literature with a meta-analysis (Q33553318) (← links)
• 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. (Q33698756) (← links)
• MicroRNAs associated with metastatic prostate cancer (Q34042888) (← links)
• Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. (Q34592125) (← links)
• Drug therapy for hereditary cancers (Q35208929) (← links)
• Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts (Q35448716) (← links)
• The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy (Q35534509) (← links)
• Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft (Q35592388) (← links)
• Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel (Q36521792) (← links)
• Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. (Q36920272) (← links)
• Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib (Q37169959) (← links)
• Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma (Q37272622) (← links)
• Tumorgrafts as in vivo surrogates for women with ovarian cancer. (Q37626455) (← links)
• Studying therapy response and resistance in mouse models for BRCA1-deficient breast cancer (Q37844487) (← links)
• Olaparib: first global approval (Q38330356) (← links)
• Ovarian and cervical cancer patient derived xenografts: The past, present, and future. (Q38508812) (← links)
• Effect of BRCA2 mutation on familial breast cancer survival: A systematic review and meta-analysis (Q38613315) (← links)
• Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. (Q38765414) (← links)
• PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma (Q38964488) (← links)
• Next generation patient-derived prostate cancer xenograft models (Q39673894) (← links)
• Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin (Q40721415) (← links)
• Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. (Q53342271) (← links)
• Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells. (Q55504427) (← links)
• Current Status of Patient-Derived Ovarian Cancer Models. (Q64969004) (← links)
• Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51 (Q90199521) (← links)
• Role of the DNA damage response in prostate cancer formation, progression and treatment (Q92734092) (← links)
• Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor (Q97540196) (← links)
• Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau (Q98154745) (← links)
• Combining PARP inhibitors with platinum or ruthenium-based complexes for cancer therapy (Q98565962) (← links)